Excelsior Sciences was delighted to speak to Brian Gormley, who covers healthcare and venture capital for The Wall Street Journal. In this wide-ranging article, Brian gives particular prominence to Excelsior Sciences’ unique capability of re-shoring small-molecule drug production by slashing the time, complexity and cost of manufacturing.
The article gives crucial context about the strategic vulnerability facing the United States when it comes to medicines, noting that the pharma industry has pledged to invest more than $350 billion by the end of the 2020s to bring manufacturing, research and development back to the U.S.
Brian performs an impressively detailed technical deep-dive, focusing on how Excelsior Sciences is pioneering a new form of chemistry that not only speeds discovery, but transforms longstanding ‘artisanal’ manufacturing processes. He compares Excelsior Sciences’ revolutionary smart bloccs platform – which replaces traditional bespoke methods with a standardized, automated process – with using prefabricated parts on an assembly line.
As our co-founder and Chief Executive Michael Foley explains, the result is that Excelsior Sciences can do things on Park Avenue as cheaply as they can be done in China or India.
